Mayne Pharma shares surge on $407 mln takeover offer from Gedeon Richter

Mayne Pharma (ASX:MYX) accepted a A$604M ($407M) takeover offer from Gedeon Richter (BU:GDRB) at A$6.40 per share, a 99.4% premium. MYX shares surged 86.3%. The deal, pending approvals, is expected to close in March 2027. Richter aims to expand its U.S. presence in women's health.

Original reporting
Published Nov 17, 2026, 1:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MYX
Bullish
high confidence
Mentioned
$MYX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYXBullishHigh
01

Why it matters

The disclosed offer price, premium, funding source, and conditionality define the takeover-arbitrage setup and the key catalysts for spread compression or widening through approvals and the shareholder vote.

02

Market read

A large, premium all-cash takeover agreement with explicit timing for shareholder vote and targeted completion is a direct, tradable catalyst for MYX takeover-arb and risk management.

03

What to watch

Completion is contingent on multiple approvals (regulatory, shareholder, court) and Mayne’s prior international business sale to Evaris, any of which can extend timelines or introduce renegotiation risk.

Relevance 9/10Novelty 9/10Timing: immediate takeover announcement and same-day surge; vote expected late Jan 2027, completion targeted March 2027

Background

Mayne Pharma is an Australian pharmaceutical company; the article states it has agreed to a scheme implementation deed for an all-cash acquisition by Gedeon Richter.

Company-level read

Ticker impact

$MYXBullishHigh confidence
Context

Mayne Pharma agreed to be acquired by Gedeon Richter for A$604 million, offering A$6.40 per share and a 99.4% premium.

Expected impact

Likely upward pressure as the market prices the takeover premium, tempered by deal-completion risk and any approval delays.

Evidence & confidence

The article discloses a fully funded all-shares cash acquisition, board recommendation, and explicit premium, which are direct inputs to takeover-arb and risk pricing.

Market effects

Highlights consolidation appetite in pharma and may increase takeover-arb interest in other mid-cap pharma names with similar strategic fit.

Could boost sentiment toward Australian biotech/pharma risk assets as deal premiums attract arbitrage flows.

Reinforces Gedeon Richter’s US expansion narrative, potentially affecting how investors underwrite women’s health and specialty pharma M&A risk.

Counterpoint

The premium may not fully hold if regulatory approvals or the required Evaris sale condition becomes contentious, creating downside in deal-spread widening.

Key entities

  • Mayne Pharma

    Subject of the takeover offer; agreed to be acquired for A$604 million at A$6.40 per share.

  • Gedeon Richter

    Hungarian pharma buyer funding the acquisition from internal cash resources.

  • Evaris Pharma

    Mayne’s previously announced sale of its international business to Evaris is a condition to deal completion.

Related articles

$CKXMedAI 8/10

Bradley S. Jacobs Plans $1B CKX Lands Deal with 10.3% Deemed Stake

Bradley S. Jacobs, through Jacobs Private Equity II, reported a 10.3% stake in CKX Lands, Inc. via a voting agreement with chairman W. Gray Stream. Jacobs plans a $1B investment, subject to approvals, which would give his firm control of CKX Lands and make him its chairman and CEO. The deal includes potential acquisitions and new stock or debt offerings.

$DASHMedAI 9/10

DOJ Takes On $17 Billion DoorDash-Instacart Grocery Deal

The U.S. Department of Justice will review DoorDash's $17 billion acquisition of Instacart, announced on Oct. 29. The deal, valued at $65 per share, would combine two major online grocery delivery platforms. The DOJ's involvement signals a federal antitrust examination, with a $1.25 billion break fee if the deal fails. Both companies expect the deal to close by late 2027 or early 2028, subject to regulatory approval.